We support your vaccine development activities
Generally, the developmental approach for vaccines is like that of comparable biotherapeutic modalities, requiring developmental activities such as formulation development, analytical development, and extensive characterization, for both drug substance and drug product. For QC release and stability testing, vaccines need assay validation.
With extensive experience across a range of biopharmaceutical modalities, we can support your vaccine development activities, operating to ICH guidelines, ICH Q2(R2) (Validation of analytical procedures); formulation development and ICH Q6B (Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products), to deliver formulation development, characterization, QC release testing and stability testing.
For several vaccine modalities, additional formulation and analytical development requirements need to be addressed for the final drug product. For optimal functionality, vaccine antigens may need to be formulated with specific delivery devices and/or immune enhancing adjuvants.